Omnicell, Inc. (OMCL)

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology for providers industry, including Omnicell (NASDAQ:OMCL) and its peers.

Here are three reasons there are better opportunities than OMCL and a stock we'd rather own. Examining a company’s long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Unfortunately, Omnicell’s 6% annual…

Earlier in May 2026, Omnicell, Inc. drew investor attention as analysts responded to its fiscal Q1 2026 results with updated research views that emphasized demand trends and product innovation across its medication management portfolio. In parallel, Wellington Management disclosed a Schedule ...

Omnicell’s Q1 2026 revenue rose to $309.9M and net income reached $11.4M, while operating cash flow climbed to $54.5M and its $350M credit facility remained fully undrawn.

Omnicell (OMCL) is back in focus after its first quarter 2026 report showed revenue of US$309.88 million, net income of US$11.36 million, and adjusted EPS ahead of expectations. See our latest analysis for Omnicell. The strong first quarter beat and higher adjusted EPS guidance have coincided ...